Trilegal Advised Maiva Pharma In Rs 1000 Crores Funding From Morgan Stanley Asia And InvAscent
Trilegal Advised Maiva Pharma In Rs 1000 Crores Funding From Morgan Stanley Asia And InvAscent
Trilegal represented Maiva Pharma Private Limited, a Bengaluru-based pure-play injectables Contract Development and Manufacturing Organization (CDMO) serving the US market, in a significant transaction. Maiva Pharma has successfully raised Rs 1,000 crores in primary and secondary funding. This funding was secured from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund - IV (InvAscent). The investment resulted in acquiring a controlling stake from existing investors and infusing primary capital into the company.
This is Maiva’s first private equity fundraise. The proceeds from the funding will be utilized by Maiva Pharma to establish a new manufacturing facility near Hosur. This facility will boast advanced capabilities in sterile dosage forms, encompassing pre-filled syringes, bags, oncology, and hormonal injectables.
The company has a US FDA, EU GMP and ANVISA (Brazilian Health Regulatory Agency) approved state-of-the-art manufacturing facility at Hosur. It has a portfolio of over 75 products for CDMO services. These products cater to more than 40 customers across the US, Canada, Europe, Australia, and LATAM markets.
The transaction was spearheaded by Corporate Partner Rahul Chugh at Trilegal, with a team consisting of Senior Associates Siddhant Maheshwari, Sidharth Dhody, and Kriti Chatrath, along with Associate Philip Ashok Alex.
